Genomictree

Genomictree launches its stool-based colon cancer early detection test, **EarlyTect-C**, marking the commercialization of its 20-year DNA methylation technology research. The South Korean diagnostics firm also outlines plans for developing a next-generation bladder cancer diagnostic. Founded in 2000, the company specializes in non-invasive cancer screening solutions.

Jul 2026BigGo FinanceNews article

Promis Diagnostics publishes clinical results for its urine-based bladder cancer test, **EarlyTect BCD Plus**, in *BJUI Compass*. The test demonstrates high sensitivity for bladder cancer detection. The study is also selected for a **late-breaking oral presentation** at the **2026 European Association of Urology (EAU) Annual Congress** in London, a leading urology conference.

Mar 2026Promis DXNews article

Genomictree is poised to dominate the US early bladder cancer diagnosis market. The company specializes in advanced diagnostic solutions, gaining traction amid rising demand for early cancer detection. Its corporate value has surged despite broader market volatility, reflecting strong investor confidence in its technology.

Dec 2024The Asia Business DailyNews article

EarlyTect BCD uses urine DNA to detect bladder cancer in patients with hematuria by analyzing PENK methylation. The test extracts DNA from exfoliated cells, applies bisulfite conversion to distinguish methylated sequences, and employs linear target enrichment and quantitative PCR in a single closed tube. PENK methylation in urine DNA signals a higher likelihood of bladder cancer presence.

Jun 2024EurekAlertNews article